Review of: "Targeting the Warburg Effect with Glucosodiene: A Case Report of a 43-year-old Female after Mastectomy of the right breast and axillary clearance with Successful First Case Treatment for Metastatic Triple Negative Breast Cancer (TNBC) of Bone"

Xuanrong Sun[1]

1 Zhejiang University of Technology

Potential competing interests: No potential competing interests to declare.

In this manuscript, the authors present a comprehensive overview of a diagnosed case involving TNBC (Triple-Negative Breast Cancer) and its treatment process. The patient initially underwent a breast X-ray examination, confirming the presence of TNBC. Subsequent analyses, such as blood and urine tests, bone scans, and cytotoxicity assays, were conducted to further assess the condition. Following ineffective conventional chemotherapy, the patient commenced treatment with glucosodiene.

Throughout the treatment, notable observations included the gradual normalization of the patient's vital signs and the absence of tumor cell activity, indicating a potential positive impact of glucosodiene on TNBC treatment. The manuscript delves into the potential mechanisms of action associated with glucosodiene, specifically discussing its role in inhibiting GLUT1 receptors and influencing intratumoral glucose metabolism.

Furthermore, the report underscores the need for extensive research and clinical trials to explore the potential efficacy of glucosodiene in treating TNBC. It emphasizes future research directions and ethical considerations in this domain.

Overall, this report offers valuable insights into novel therapeutic approaches for TNBC, making it a pertinent reference for future clinical investigations. .Therefore, I suggest it be accepted after the author complements the content, articulates the obscure content, and corrects the format.

1. The Figure 2 in the paper is not particularly clear. Are there clearer images available for readers' analysis? Additionally, could the relevant lesions expressing Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2/neu (Human Epidermal Growth Factor Receptor 2) be highlighted or circled on the image?

2. The scanned image in Figure 3 appears somewhat irregular. Would it be possible to adjust or enhance its quality for better clarity and consistency?

3. Could a summary timeline of the patient's medical history and treatment processes be created without breaching ethical guidelines?

4. Is it ethically permissible to create visual representations, such as graphs or charts, depicting the patient's post-treatment blood and biochemical parameters?

5. Minor punctuation errors were identified in the abstract, around the sixth line, and in the discussion section, at the

beginning of the ninth line. These need to be revised for clarity and correctness.